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SUMMARY
Recognising that halothane is declining as the volatile 
anaesthetic agent of choice for inhalational induction and that 
isoflurane is replacing it, particularly in North America and 
Europe, this study was designed to determine whether isoflurane 
is comparable to halothane with respect to speed of induction
and complication rate when used for rapid inhalational induction 
(RII) of anaesthesia.
Isoflurane, administered in oxygen or in nitrous oxide and
oxygen, was compared to halothane, administered in oxygen, for 
RII in healthy, unpremedicated patients. Isoflurane, in both 
carrier gas mixtures, produced a faster RII than halothane. 
Complication rates and patient acceptance was similar for all 
three groups. Haemodynamic stability in patients subjected to
RII with halothane and isoflurane was remarkable.
The candidate concludes that isoflurane is a useful agent for
RII and is a viable alternative to halothane when 
contraindications exist to its use.
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CHAPTER 1 
INTRODUCTI ON
1
1 . 1 THE DEVELOPMENT OF INHALATIONAL ANAESTHESIA
The inhalational route of administration of anaesthesic agents 
has been used since the first demonstration of general 
anaesthesia (GA) using ether, at the Massachusetts General 
Hospital by William Morton on October 16th, 1846 This 
followed the failed attempt to demonstrate the effect of 
nitrous oxide (N^O) by Horace Wells in 1845 at the same 
hospital
Inhalational induction of anaesthesia as a technique is 
therefore as old as general anaesthesia itself. As newer agents 
have been developed for GA, many have been administered by this 
route. The inhalational route was, until comparatively recently, 
used for both the induction as well as the maintenance of 
anaesthesia, and the volatile agent used for this purpose, was 
often used as the sole anaesthetic agent. Ether is still used in 
this manner in many developing countries. Surgical anaesthesia, 
Stage 3 of anaesthesia as defined in Table 1 on page 5, is 
induced using an inhalational technique. Once an adequate level 
of anaesthesia has been achieved, the concentration of the 
volatile agent, such as ether, is decreased and the same agent 
is used for maintenance of anaesthesia. This provides a simple 
and safe anaesthetic technique that is essentially the same as 
that first demonstrated in 1846.
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Despite the safety of the above technique, it has the 
disadvantage that induction of anaesthesia is very slow. This is 
especially true for the agents with highbloodrgas solubility 
coefficients (for a definition of solubility coefficient, see 
Figure 1, page 4), such as ether and methoxyflurane. Ether has 
bloodrgas solubility properties similar to methoxyflurane (B/G 
12,1 vs. 13) and consequently a graph tracing like that shown 
for methoxyflurane in Figure 1, page 4. The speed of induction 
of anaesthesia with the inhaled volatile agents depends on the 
speed at which an adequate concentration of the agent is reached 
in the brain. This in turn is dependent on the concentration 
gradient of the agent between the circulation and the brain. The 
concentration of the agent in the circulation is determined by 
the rate of rise of concentration of the volatile agent in the 
alveoli and passive diffusion of the agent from the alveoli to 
the circulation. Agents such as those mentioned above, which 
have high blood gas solubility coefficients have a slow rate of 
rise of alveolar concentration. This is depicted in Figure 1 by 
classical "wash-in" curves.
The stages of anaesthesia related to the use of ether were 
defined by Plumley in January 1847. These stages were 
codified by Guedel during World War I and in 1943 Gillespie 
added reflex responses to the signs related to the stages of 
anaesthesia as defined by Guedel The stages of 
anaesthesia as defined by Gillespie are shown in Table 1
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F -  i n s p i r e d  c o n c e n t r a t i o n .
FIGURE 1. The Rate of Rise of Alveolar Concentration of 
Anaesthetic Agents ^
Definitions of Solubility Coefficients
The Bunsen solubility coefficient is the volume of
gas, corrected to standard temperature and pressure,
which dissolves in one unit volume of the liquid at
the temperature concerned, where the partial pressure
of the gas above the liquid is one standard atmosphere
pressure.
The Ostwald solubility coefficient is the volume of 
gas which dissolves in one unit volume of the liquid 
at the temperature and pressure concerned.
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TABLE The Stages of Anaesthesia as Defined by 
Gillespie ^
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From Table 1, it is evident that stage 2 of anaesthesia can be 
stressful for both the patient and the anaesthetist. Attempts 
were therefore made to ameliorate the effects of this stage. 
Premedication with a sedative or opioid drug and an 
anti-sialogogue, such as atropine, went some way towards 
decreasing the excitatory and upper airway responses of stage 2 
anaesthesia. However, heavy premedication and the slow recovery 
inherent in the use of an agent such as ether, prolonged the 
recovery phase of general anaesthesia. Intravenous induction of 
anaesthesia was then developed to overcome the slow induction 
provided by the inhalational agents.
1.2 THE INTRODUCTION OF INTRAVENOUS INDUCTION OF 
ANAESTHESIA
As described above, intravenous induction agents were developed 
to meet specific requirements in anaesthetic practice. One of 
these was to provide a rapid induction of anaesthesia, which was 
both pleasant and safe for the patient.
As with most advances in anaesthesia, the development of a 
viable intravenous (IV) anaesthetic induction agent was a 
slow process. It began with the discovery of the first 
barbiturate, malonyl urea or barbituric acid, in 1864 by Adolf 
von Baeyer This was followed by the first use of 
methyl-propyl-carbinol-urethane (Hedonal) to produce sleep by 
Krawkow in St. Petersburg in 1905 All the barbiturates
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available at this time had the disadvantages of slow onset and 
prolonged duration of action. The disadvantage of slow onset was 
overcome by the development of hexobarbitone and the 
thiobarbiturates in the 1930's Thiopentone, one of the
thiobarbiturates, remains one of the most popular IV induction 
agents today.
Since the introduction of the thiobarbiturates, various other IV 
agents have been developed, such as ketamine (1965), etomidate 
(1973) and propofol (1977). All these agents have been developed 
with the same objectives as the original IV agents - to provide 
a safe rapid induction of anaesthesia. In this regard they have 
largely succeeded, following the inevitable mishaps which occur 
during the initial introduction of new drugs.
Therefore, by the 1930's the trend for modern anaesthetic 
practice had been set. This provided for a rapid IV induction 
followed by maintenance of anaesthesia with a volatile agent. 
This technique also has the advantage that it carries the 
approval of most patients when compared to the original 
inhalational technique described in Section 1.1 above. Since the 
days of ether, however, there have been marked advances in the 
field of volatile anaesthetic agents.
1.3 THE NEWER VOLATILE ANAESTHETIC AGENTS - HALOTHANE, 
ENFLURANE, ISOFLURANE, SEVOFLURANE AND DESFLURANE
The development of volatile agents in the light of improved 
understanding of structure-activity relationships began only in
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the 1930's As fluorine chemistry advanced it became
possible to exploit the properties which fluorination of
molecules imparted to the volatile agents, namely
i q \
non-combustibility, low toxicity and stability v From the 
vast number of agents tested we now have three fluorinated 
volatile agents for use in clinical practice; halothane,
enflurane and isoflurane. Two further agents are now undergoing 
clinical trials: sevoflurane and desflurane.
In addition to the improved stability and increased potency of 
these agents compared to older inhalational agents such as ether 
and chloroform, they also provide for a much more rapid
induction of anaesthesia. This is related to their physical 
properties, and especially their bloodrgas solubility 
coefficients (see Figure 1). Other physical properties of 
importance when considering the newer volatile agents are -
- lipid solubility of the agent, which is often defined
as the oil: gas solubility coefficient. This relates to 
the potency of the agent. The more lipid soluble an 
agent is, the more potent it is and
- boiling point. This gives an indication of the 
volatility of an agent.
The physical properties of ether, chloroform and the newer 
volatile agents are shown in Table 2 (^,11)
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TABLE 2 PHYSICAL CHARACTERISTICS OF SOME OF THE INHALATION ANAESTHETIC AGENTS (9,11)
Chloroform Ether Desflurane Sevoflurane Isoflurane Enflurane Halothane
Molecular weight 
(Da)
119.0
Boiling point
f c )
-
Vapour pressure 
at 22 °C (kPa)
23.0
Partition coefficients 
Blood: gas 
Oil: gas
8.4
265.0
Preservative None
Stability in moist 
soda-lime Stable
MAC in oxygen 0.7
74.0 168.036 200.053
- 23.5 58.5
59.0 88.53 21.33
12.1 0.4 0.6
65.0 19.0 53.0
None None None
Stable Stable Unstable
1.92 -6.0% -2.0%
184.491 184.491 197.381
48.5 56.5 50.2
31.86 22.93 32.53
1.4
91.0
1.9
96.0
2.3
224.0
None None Thymol
Stable Stable Stable
1.2% 1.6% 0.7%
MAC - See Appendix,  page 81.
It is evident from the above that the newer agents offer a 
number of advantages over the original volatile anaesthetic 
agents such as ether. They are capable of rapidly inducing 
anaesthesia, as they all have relatively low blood:gas (B/G) 
solubility coefficients. For the same reason, it is possible to 
rapidly vary the depth of anaesthesia by adjusting the inhaled 
concentration of the volatile agent. At the end of an 
anaesthetic, these insoluble agents are quickly exhaled and 
eliminated from the body as the gradient used for induction of 
anaesthesia (from inspired gas — > the alveoli — > the 
circulation — > the brain) is reversed. Therefore, a rapid 
anaesthetic induction, followed by anaesthetic maintenance, 
which is easily variable in depth, and then a rapid recovery are 
possible with a single agent.
As all the IV agents produce some post-operative sedation 
(variable in intensity and duration), it would seem ideal to be 
able to avoid these agents if it were possible to do so, by use 
of only a volatile agent in the anaesthetic technique. Venous 
puncture may be avoided if intravenous agents are not used in 
the anaesthetic technique. This is a factor in children and 
patients with a needle phobia. If a rapid recovery were desired 
and if the speed of induction using the volatile agent matched 
that of the IV agent then an inhalational technique may be used 
to replace IV induction. These, essentially, are also the 
indications for inhalational induction of anaesthesia.
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1 . 4 INDICATIONS FOR INHALATIONAL INDUCTION OF ANAESTHESIA
The indications for inhalational induction of anaesthesia are 
the same as those for the avoidance of intravenous induction. 
These indications would include -
- the avoidance of the use of needles, especially in 
paediatric practice, in nervous adults with a needle 
phobia and in mentally retarded patients;
- patient allergy to the IV drug chosen for the
technique,
- if the "hangover" (post operative sedation) effect of
the IV drug were to be avoided, as in out patient
anaesthesia,
- induction of anaesthesia in patients with compromised 
upper airways, where IV induction may result in loss 
of control of the airway and possible consequent 
hypoxia in the patient and
- if the patient prefers the technique of inhalational 
induction.
The above list includes both relative and absolute indications 
for inhalational induction of anaesthesia. Of the volatile
agents available, halothane is the agent of choice for
inhalational induction of anaesthesia. This is so because 
halothane has a pleasant odour, is well accepted by patients and 
is economical. Due to its lack of pungency, it does not readily 
produce unwanted respiratory tract side effects, such as
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coughing, laryngospasm and excessive secretions. Various 
studies, including one by Phillips, Brimacombe and Simpson 
show that even though halothane is more soluble 
(higher B/G solubility coefficient) than isoflurane, it 
produces a faster inhalational induction. This is attributed to 
its lack of airway complications and smoother induction. 
However, since shortly after its introduction into clinical
anaesthetic practice there have been concerns that halothane is 
able to produce a fulminant hepatitis in susceptible 
individuals (^).
Recently, the Committee on Safety of Medicines (CSM) in the
United Kingdom published guidelines relating to the use of 
halothane This and other publications has resulted in
the decline of the use of halothane in Britain and North 
America. Isoflurane is becoming the volatile agent of choice and 
methods are being sought to make this agent more
patient-acceptable for use as an inhalational induction agent. 
One of the methods employed to make isoflurane more
patient-acceptable has been to administer it by the technique of 
Rapid Inhalational Induction (RII).
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1.5 CONVENTIONAL INHALATIONAL INDUCTION (Cl I) and RAPID 
INHALATIONAL INDUCTION (RII)
CII is the technique by which anaesthetic vapours and gases have 
been used to achieve anaesthetic induction since the discovery 
of ether. It involves the slow incremental increase of the 
concentration of the vapour or gas in the inspired gas as the 
patient breathes. This causes the patient to pass slowly through 
the stages of anaesthesia as described in Table 1. This also 
causes the patient to pass slowly through stage 2, the stage of 
excitement, with the complications related to this stage (see 
Table 1). As discussed, the less soluble the agent is the faster 
the agent will achieve adequate concentrations in the brain and 
exert its anaesthetic effect. It follows then that the less 
soluble the agent is the faster the various stages of 
anaesthesia will be achieved. Halothane (B/G solubility 
coefficient = 2,3) will therefore produce a faster inhalational 
induction than ether (B/G solubility coefficient = 12,1). Also, 
the time the patient spends in stage 2 of anaesthesia will be 
shorter for halothane than for ether, as examples. So, although 
halothane is used in the same manner as ether was originally 
used, the induction sequence is faster and more pleasant for the 
patient due to the improved physical properties of halothane 
over ether, as previously discussed.
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RII is a technique originally described for the use of 
cyclopropane, an anaesthetic gas with a low B/G solubility 
coefficient The technique requires the patients to take 
5 or 6 deep breaths of a high inspired concentration of 
cyclopropane. This produces a rapid increase in the alveolar 
concentration of the anaesthetic agent and subsequent loss of 
consciousness. Stage 3 of anaesthetic depth is achieved in a 
very short time and the complications related to stage 2 
avoided. This technique is described more fully in Chapter 4. 
This technique would seem well suited to the use of isoflurane 
in that the physical properties of isoflurane should make it 
superior to halothane in terms of speed of induction. Also, if 
consciousness is rapidly lost, then the pungency of isoflurane 
will not be experienced by the patient for a prolonged time (ie. 
less so than if isoflurane were administered by CII). Isoflurane 
should also produce a more rapid induction and recovery than 
halothane as it is the least soluble of the volatile agents 
presently available for clinical use.
The use of both halothane and isoflurane have been investigated 
for RII (see Chapter 2). However, isoflurane has not been used 
for RII without the addition of either heavy premedication or 
nitrous oxide in the inspired gas to limit the airway side 
effects of the agent.
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CHAPTER 2 
LITERATURE REVIEW
15
The English language literature regarding Rapid Inhalational 
Induction (R11) is not extensive. This is because RII is a 
relatively new technique with a limited application.
In 1982 a study by Ruffle, Latta and Snider introduced 
the concept of RII with one of the modern volatile agents, 
halothane, and compared the technique to conventional 
inhalational induction (CII). The more rapid onset of 
anaesthesia obtained by RII, as well as other advantages of the 
technique over CII were discussed. In a subsequent study the 
same authors studied the technique of anaesthetising patients 
with 4% halothane in oxygen (02) by RII that they had employed 
for the previous 5 years The study population consisted 
of healthy male and female volunteers who were anaesthetised 
with halothane in 09. They were given 1,2,3 or 4% halothane in 
02- The volunteers took a vital capacity breath (VCB) of the 
particular concentration of halothane in 02, and then held the 
breath for as long as possible. They then continued to breathe 
the same concentration of halothane in 02 that had been 
administered for the VCB until unconsciousness ensued. Loss of 
consciousness (LOC) was defined as lack of response to verbal 
commands. All the volunteers had each of the halothane 
concentrations administered to them. They were allowed to wake 
up between the administrations of the different concentrations. 
During the induction sequence physiological variables such as 
heart rate (HR), blood pressure (BP) and arterial oxygen
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saturation (SpC^) were recorded. Inspired and expired gases 
were analysed on a breath by breath basis by means of a mass 
spectrometer.
The authors concluded that 4% halothane in Og, administered in 
the manner described above, rapidly produces unconsciousness 
without significant impact on the physiological variable 
measured. The volunteers also found this to be a not unpleasant 
experience. The rapid LOC is ascribed to the rapid rate of rise 
of halothane in the expired gas, and by inference the alveolar 
gas, produced by this agent. Of interest is the fact that most 
of the study population experienced amnesia after the first VCB, 
although they responded to verbal commands for some time after 
this period and before LOC. The authors suggest this may account 
for the high degree of acceptance of the technique - as the 
subjects could not remember the induction sequence they did not 
find it unpleasant. 4% halothane in was f°und to be most 
effective for the technique of RII. This supported their 
previous practice of using this concentration in the preceding 5 
years in healthy patients. The authors state that 2 - 4 %  
halothane in 0  ^ is "effective, safe and well accepted by 
healthy young adults". They also state that RII is not useful or 
safe in patients with poor lung function or in senile, young or 
retarded patients who cannot co-operate with the manoeuvres 
required for RII.
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In 1986 Wilton and Thomas described a technique of RII,
which they called the "single breath induction" technique. Their 
study population consisted of 100 unpremedicated outpatients. 
The patients' ages ranged from 17 - 90 years. The method of
administration of the anaesthetic gas mixture was similar to 
that used by Ruffle and co-workers, but differed in the 
following aspects -
- the anaesthetic gas mixture contained 66% nitrous 
oxide (N20), 33% oxygen (02) and 4% halothane, and
- the mixture was administered to the patients by means
of a modified Mapleson A breathing system, instead of 
the circle breathing system used by Ruffle and
colleagues. (The details of the modified Mapleson A 
system are to be found in Chapter 4).
The rationale for using N20 in the anaesthetic mixture, as 
stated by these authors, is that N20 decreases the
concentration of halothane required to induce anaesthesia and 
therefore shortens the induction period and will "minimise the 
cardiovascular depression that tends to occur with
halothane-oxygen anaesthesia". These authors defined LOC as loss 
of the eyelash reflex, a level of anaesthesia deeper than that 
defined by lack of response to verbal command as defined by 
Ruffle and co-workers. Induction time (onset of the VCB to LOC) 
was not quantified by Ruffle and associates in actual time (they 
mention approximately 2 min. after a breath hold of 30-90 sec. 
or 5 breaths after the VCB). Ruffle and Snider in a
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separate study, compared induction time with RII to conventional 
inhalational induction (CII) and determined times of 112 sec. 
(RII) compared to 164 sec. (CII). Wilton and Thomas found that 
their technique produced an induction time of approximately 
81-84 seconds.
This study by Wilton and Thomas again demonstrated the 
small impact RII has on physiological variables such as HR and 
BP - the effect is comparable to that seen after a barbiturate 
intravenous (IV) induction. Ninety-one percent of the patients 
in this study sample found RII to be acceptable. This again is 
probably because most of the patients have no conscious recall 
after the VCB.
Of interest is the explanation given by the authors for the poor 
correlation between the period that the patient held the VCB and 
the induction time. The N£0 in the inhaled mixture will ensure 
continued halothane uptake during the period of apnoea 
(breath-holding) by the so-called second gas effect (see 
Appendix, page 81). On the other hand, if the patient continues 
to breath the gas mixture and not hold his/her breath after the 
VCB, then the rate of rise of halothane concentration in the 
alveoli is assured (see "wash-in curves" in Chapter 1) by 
alveolar ventilation.
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The above studies prompted an editorial in the Lancet 
entitled "Inhalational Induction of Anaesthesia - New
Inspiration". This editorial succinctly described the problems 
of C11; patients' fears of the anaesthetic mask, a slow onset of 
anaesthesia and a relatively high incidence of excitatory 
phenomena as the patient passes through the second stage of 
anaesthesia. It also emphasised the possible drawbacks of IV 
anaesthetic induction; namely possible marked hypotension,
frequent post-induction apnoea and the "hangover" effect.
The mechanism of induction of anaesthesia by inhaled volatile 
agents was briefly described in the editorial. LOC occurs when 
an effective drug concentration is achieved in brain tissue. As 
the volatile anaesthetics are highly lipid soluble, there is a 
close correlation between their level in arterial blood and the 
brain. There is also (unless there is severe lung disease) a 
close relation between the alveolar concentration and the 
arterial blood concentration. Therefore, the rate of onset of
anaesthesia is largely dependent on the rate of rise of the
alveolar concentration of the anaesthetic agent. RII provides 
for this rapid rise in alveolar concentration, and subsequently 
a rapid onset of anaesthesia.
The author then goes on to review the studies described 
previously in this Chapter and concludes that RII offers
advantages over CII (more rapid loss of consciousness) and IV 
induction (no venepuncture before the patient is asleep,
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avoidance of the risk of anaphylaxis associated with IV agents, 
avoidance of the "hangover" effects seen with IV agents and a 
smooth transition from induction to maintenance of anaesthesia).
At the time of publication of this editorial, isoflurane and 
enflurane had not yet been used for RII and the author predicts 
that, because of their pungent "aroma", RII with these agents 
would be slower than that seen with halothane, despite the more 
rapid rate of rise of alveolar concentration associated with 
these agents (due to their lower B/G solubi 1 ity coefficients). 
Mention is also made of the concern about hepatic damage 
following the administration of halothane.
The overall conclusions reached in this editorial were that RII 
offers some advantages over both CII and IV induction, but that 
the field of application of RII is rather limited. The 
limitations included: (i) RII cannot be recommended as the 
principal indication for inhalational induction in adults where 
there is anticipated difficulty in control of the upper airway, 
(ii) RII does not induce anaesthesia as fast as IV induction (83 
sec. vs. 15-30 sec.) and (iii) a fully co-operative patient is 
required. There is also the concern about the use of halothane, 
in the face of reports on its hepatotoxicity.
21
Certain questions are prompted by this article - is it possible 
to use another volatile agent for RII, and how would it compare 
to halothane when used for RII ? Also, would one of the less 
soluble agents (enflurane or isoflurane) provide a faster RII 
than halothane?
The next article to appear in the literature was one by Loper 
and co-workers (20). This study compared halothane and 
isoflurane for RII. The study population was made up of adults 
belonging to the American Society of Anesthesiologists (ASA) 
physical status I and II categories (see Appendix, page 81). 
They received a RII with 4,5 MAC equivalents of either halothane 
or isoflurane in oxygen as the carrier gas. The investigators 
acknowledged the pungency of the isoflurane vapour and 
consequently administered a relatively large dose (5mcg/kg) of 
fentanyl IV 5 min. prior to RII with either of the above agents 
in order to limit the cough reflex. During induction, with the 
vapour delivered from a circle absorber breathing system, HR, 
BP, SpC^, end expired carbon dioxide (PE COg) and 
electroencephalographic (EEG) measurements were made.
Using the lack of response to verbal command as well as loss of 
the eyelash reflex as the end points, the authors found that 
time to LOC was significantly shorter with isoflurane (38 sec.) 
than with halothane (86 sec.). There were no significant 
differences in cardiovascular and respiratory parameters between 
the two groups. The EEG pattern showed a greater excitatory
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phase when halothane was used compared to isoflurane. All the 
patients in the study group found RII to be acceptable, as 
determined at patient interview on the day after the 
anaesthetic. All the patients were amnesic for events in the 
induction sequence following the VCB containing the volatile 
agent.
This study then answered the questions prompted by the Lancet 
editorial. However, the study may be criticised on the following 
points. The dose of fentanyl administered prior to RII is 
relatively large and as pointed out in a letter to the editor by 
Lamberty it is surprising that the patients "breathed at 
all afterwards!" Also, no mention is made of how the patients 
were "surveyed" on the day after the RII. Because of the 
fentanyl used in these patients, the induction times described 
cannot be extrapolated to the day-case anaesthesia situation, 
where rapid recovery is desirable. This study does not, 
therefore, describe the use of isoflurane for RII in patients 
who are to have short surgical procedures and in whom a rapid 
recovery is desired.
An article by Lamberty and Wilson goes some way to 
clarifying the use of isoflurane for RII in unpremedicated 
patients, such as would present for day-case anaesthesia. They 
compared isoflurane for CII and RII in 72 ASA I and II patients 
presenting for day-case (outpatient) anaesthesia. Evaluation of 
complication rates between the two groups showed a lower
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incidence of all the following complications in the RII group 
compared to the CII group; coughing, laryngospasm, breath 
holding, excitatory phenomena (movement) and airway secretions. 
Cardiovascular (CVS) stability was a feature of both groups.
The RII group received a VCB, from a modified Mapleson A 
breathing system, containing 2% isoflurane in 66% N^O and 33% 
of Og. The CII group received 0,5% increments of isoflurane in 
66% N2 O in O2 every 5 breaths in the induction sequence. The 
patients were not pre-oxygenated.
The authors also recognised the potential for isoflurane to 
cause airway complications due its pungency and used NgO in 
the inhaled anaesthetic mixture to limit the inspired 
concentration of isoflurane. They note the high degree of 
patient acceptance of RII (94%) compared to CII (74%). Once 
again, the rapid onset of amnesia for events in the induction 
sequence was demonstrated. Patients in the RII group had recall 
for a median 2 breaths, while those in the CII group had recall 
for a median 5 breaths in the induction sequence.
This study assessed the patient's co-operation with the 
techniques of RII and CII - ie how well they understood and 
complied with the maneouvres required during the induction. The 
findings show that there was less patient co-operation with RII 
than CII. This is not surprising, as in CII normal spontaneous 
respiration is all that is required, whereas with RII specific 
respiratory manoeuvres are required.
24
In their discussion, Lamberty and Wilson point out that the 
longer induction times predicted in the Lancet editorial 
for RII with isoflurane was not confirmed. They also note the 
potential problems of halothane use (hepatic damage) and suggest 
that if isoflurane is to be used, then RII is a viable and safe 
technique with less complications than CII with isoflurane. They 
suggest that this lower complication rate is because the patient 
passes through the second stage of anaesthesia more rapidly with 
RII than with CII - akin to the effect of IV induction in taking 
the patient from being awake to stage 3 of anaesthesia rapidly. 
They do not make any attempt to determine induction times 
though, nor do they define LOC.
They also note that in the inductions which had to be abandoned, 
one in each group, both the patients were smokers and suggest 
that RII is not viable in smokers or patients who have other 
causes for airway irritability. This conflicts with the findings 
of Ruffle and co-workers who advocate the technique for
all patients, regardless of smoking history.
An editorial by Drummond in the British Journal of
Anaesthesia discusses the technique of RII, its implications and 
uses and poses some questions regarding the technique. Reference 
is made to the 1987 study of Ruffle and Snider in which
a variation of the technique of RII is described - the subjects 
take three VCB's interspersed with breath holds instead of the 
single VCB. This technique halved the time to LOC to
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approximately 1 min., compared to the 2 min. period to LOC 
obtained by the technique described in the previous paper by 
Ruffle and co-workers
The mechanism of action of production of LOC by RII is likened 
by Drummond to a "bolus", rather than an "infusion" technique 
(ie CII). If a VCB of 4 litres is taken by the subject and the 
inspiratory - expiratory halothane difference is 3%, then 120ml 
of halothane vapour has been taken up by the pulmonary 
circulation. This will produce a rapid rise in anaesthetic agent 
concentration in the arterial blood and consequently the brain. 
This results in rapid LOC. If loss of eyelash reflex is used as 
the end-point and isoflurane is the agent being used, the the 
time to LOC is approximately 38 sec. The author postulates that 
this time, which is almost as fast as IV induction, may be the 
fastest time possible using an inhalational induction technique.
Drummond also makes the point that for induction to proceed and 
for the patient to lose consciousness alveolar ventilation (VA) 
must continue - ie. anaesthetic agent must continue to be taken 
up. Two factors may interfere with continued alveolar 
ventilation and uptake of volatile agent; the first is 
respiratory depression by the volatile agent and the second is 
reflex apnoea and coughing due to reflexes elicited by the 
volatile agent causing airway irritation. The author discusses 
the possible problems due to airway irritation, when isoflurane 
is used. He also states that although 2% isoflurane administered
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by R11 is less irritant than isoflurane CII (quoting the paper 
by Lamberty and Wilson v it may be that it is still more 
irritant than when halothane is used. He stated that there was 
no well-controlled trial comparing RII with halothane and 
isoflurane in unpremedicated patients. This statement forms the 
basis for the dissertation by this candidate.
The breath-holding part of RII is described as useful by 
Drummond because is retained and provides a stimulus to 
respiration in the patient who may be apnoeic following RII.
He also states that, theoretically, ^ 0  in the induction 
mixture may produce an increased incidence of excitation. This 
is because the less soluble and more rapidly acting ^ 0  
produces a light plane of anaesthesia (stage 2) with the 
accompanying restlessness, before the less soluble volatile 
agent produces stage 3 anaesthesia.
In his review of preceding studies of RII the author states that 
various end-points of RII (ie definitions of LOC) had been used 
in the various studies and that none of these were equivalent to 
surgical anaesthesia. He concludes the editorial with the words 
"there is no doubt regarding one advantage this method; prompt 
and full recovery".
The Candidate is unaware of any studies of RII reported in 1989. 
In 1990 there were only two references regarding the topic. The
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first is a paper from Japan by Rowbottom and associates 
comparing enflurane for RII and enflurane for ClI. 4% enflurane 
in 67% ^ 0  and 0^ taken by VCB was compared to Cl I with 
enflurane in 30 surgical patients. LOC was defined as loss of 
eyelash reflex and lack of response to verbal commands. All the 
patients were premedicated with atropine and secobarbitone. The 
authors found RII to produce a faster induction than CII (71 
sec. vs. 132 sec.), and was acceptable in 87% of patients. There 
was no difference between the two techniques in the impact on 
physiological variables. There was a low incidence of airway 
irritation in both groups, probably due to the premedication, 
since enflurane has a very pungent odour. Of interest is the 
fact that only 50% of patients had amnesia after the VCB in the 
RII group. This is a much lower figure than that obtained in the 
studies using halothane and isoflurane quoted previously in this 
Chapter.
The other 1990 reference to RII is a letter by Mackenzie from 
Oxford in which he reports a pilot study using 5%
isoflurane in O2 for RII in children aged 7 months to 13 
years. ^ 0  was omitted from the inhaled mixture to avoid the 
excitatory phenomena associated with its inclusion (see above). 
Older children were asked to breath three times deeply and 
younger children merely had the mask applied to their faces. 
Rapid times to LOC are described (45-60 sec.), but the criteria 
for definition of LOC are not mentioned. The author states that 
older children found the odour "particularly unpleasant", as no
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doubt did the younger children who did not voice their opinions! 
This again highlights the problem of pungency associated with 
the use of isoflurane.
(12 271There are numerous other references v ’ ' related to the
pungency and airway complications of isoflurane. However, one 
recent study has shown that the simple manoeuvre of humidifying 
the carrier gas during CII with isoflurane decreased the 
incidence of respiratory complications (^8)
The investigation by this candidate was undertaken to answer 
some of the questions raised by the above studies of RII.
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CHAPTER 3 
STUDY DESIGN- 
MATERIALS AND METHOD
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3.1 STATEMENT OF THE PROBLEM
As discussed in Chapter 2, the literature review, there are 
various aspects of Rapid Inhalational Induction (R11) that 
require clarification. This study was designed to address the 
following aspects of RII -
1. To determine whether it is possible to administer
isoflurane during RII to unpremedicated patients
without inducing a high incidence of respiratory tract 
side effects.
2. To compare halothane and isoflurane in equipotent
doses for RII in patients presenting for day-case
anaesthesia.
3. To compare RII with 5% isoflurane with the
technique described by Lamberty and Wilson (see 
Chapter 2), where 2% isoflurane is used in nitrous 
oxide (NgO) and oxygen (O2 ).
4. To measure the impact on heart rate (HR), blood
pressure (BP) and arterial oxygen saturation (SpC^) 
produced in patients by the techniques of RII listed in 
(2) and (3) above.
5. To determine the comparative side effects observed 
when the techniques listed in (2) and (3) above are 
used.
6. To determine the relative speeds of induction when
the above methods are used for induction of
anaesthesia.
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7. To survey the study participants as to the
acceptability and immediate post-operative side effects 
of the above techniques.
The study would not make any attempt to address the question of
emergence from anaesthesia.
3.2 THE NULL HYPOTHESES
These may be listed as follows -
1. It is not possible to administer isoflurane to 
unpremedicated patients during R11;
2. Isoflurane 5% does not produce a faster RII than 
halothane 3.5%.
3. 2% isoflurane in NgO and Og does not provide for a
slower RII than when a higher concentration of
isoflurane (5%) is used.
4. 3,5% halothane (4,5 MAC) does not produce a slower RII 
than either 2% or 5% isoflurane.
5. There will not be a higher incidence of restlessness in 
the patients receiving N^O in the inhaled mixture.
6. The incidence of respiratory tract side effects will be 
similar for all the groups entered into the study.
7. 2% isoflurane in N£0 and 0  ^ will not produce the
least effect on BP and HR, compared to the other two 
groups.
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3.3 STUDY POPULATION AND PATIENT SELECTION
Sixty (60) ASA (American Society of Anesthesiologists) physical 
status I and II patients presenting for day-case dental surgery 
(extraction of wisdom teeth) at the Dental Hospital of the 
University of the Witwatersrand were entered into the study. 
Institutional Ethical Committee approval was obtained and 
informed consent was obtained from all the patients. The study 
was also approved by the Pharmaceutical and Therapeutics 
Committee of the University of the Witwatersrand (Clearance 
number 89/1/27).
All consenting patients were entered into the study. Exclusion 
criteria included the following -
- any chronic pre-operative medication ie. chronic 
medication for a pre-existing medical condition;
- mass less than 30 kilograms (kg), to obviate the need 
to use different anaesthetic breathing systems;
- ischaemic heart disease - this was defined as any 
history of anginal attacks or previous myocardial 
infarction;
- age less than 12 years or more than 65 years;
- compromised upper airway eg. trismus, intra-oral 
abscess.
All other consenting patients were entered into the study group 
regardless of smoking history or degree of pre-operative
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anxiety. All were given the choice of withdrawing from the study 
at any time (see the sample consent form).
The patients were admitted to the hospital either on the night 
before operation or on the morning of surgery. During the 
admission formalities, completed by the nursing staff, the 
patients were presented with a Consent Form and asked to peruse 
it. The candidate performed a pre-operative assessment on all 
the patients on the morning of surgery, and at this point asked 
the patients whether they would consent to enter the study and 
whether they had any questions arising from their study of the 
consent form. Written consent was then obtained from those who 
agreed to enter the study.
All the patients in the study group were randomly allocated to 
one of three groups on entering the Operating Theatre (OT). 
Randomisation was achieved by placing slips of paper labelled as 
follows in sealed envelopes -
-  2% iso/N^O/O^
- 5% iso
- 3,5% hal.
Twenty (20) of each of these slips of paper were placed in 
individual envelopes resulting in a total of 60 envelopes. The 
envelopes were then numbered from 1 to 60 and placed in random 
order. Random numbers were generated by a statistics program 
("Epistat") on a Triton personal computer.
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ISOFLURANE STUDY CONSENT FORM Sample
You are due to have an operation today/tomorrow. While the 
operation takes place you will be anaesthetised (put to sleep), 
so that you feel no pain and are not aware of what is happening. 
The usual method of putting patients off to sleep involves 
giving them an injection into a vein, of a short-acting 
anaesthetic medication. The effect of this medication wears off 
within a few minutes and the patient is then kept asleep by 
means of an anaesthetic vapour. He breathes this in and out for 
the duration of the operation. At the end of the operation the 
vapour is turned off and the patient regains consciousness.
The reason why the anaesthetic starts off with an injection is 
because the injection takes effect very quickly. In the past 
this avoided any unpleasantness the patient may have experienced 
from breathing pungent anaesthetic vapours, such as ether, 
before they lost consciousness. However, newer anaesthetic 
vapours are very potent and a new method has been developed 
whereby a single deep breath of these vapours can induce 
unconsciousness. The advantages of this technique are that the 
injection is not required and the patient wakes up faster at the 
end of the operation. The patient also has less of a "hangover" 
after the operation with this technique. The disadvantages are 
that the patient may find it uncomfortable to breathe from the 
anaesthetic mask before they are asleep or may find the smell of 
the anaesthetic vapour unpleasant.
I am presently conducting a trial into the use of two new 
anaesthetic vapours, halothane and isoflurane, for this new 
"single breath" technique. Both these vapours have been used in 
anaesthetic practice for a number of years and have been shown 
to be safe. I should be grateful if you would consider taking 
part in this trial. All that would be different from the 
anaesthetic that you would normally receive would be that you 
are not put off to sleep with an injection, but by means of 
taking a single breath of one of the above vapours from a mask. 
If at any stage you would prefer to be put off to sleep with an 
injection instead, or if you find the mask uncomfortable at all, 
then I will put you off to sleep in the normal fashion (with an 
injection).
I, the undersigned consent to take part/qive consent for my 
child to take part in the above trial, as explained to me by Dr. 
van Heerden. I understand that if I do not wish to take part/do 
not wish my child to take part in this trial that this will in 
no way prejudice my anaesthetic care/the anaesthetic care of my 
child. I also understand that I may change my mind about 
entering/my child entering this trial at any stage without 
prejudice to myself/my child.
PATIENT/GUARDIAN ...............................................
WITNESS ........................................................
DATE ...........................................................
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As each patient arrived in the OT, an assistant opened an 
envelope which indicated to him the vaporiser setting on the 
anaesthetic machine to be used for that particular patient. He 
then adjusted the vaporiser and gas flows as indicated by the 
random selection slip of paper, as described in the Methods 
section 3.5 below. The candidate was unaware of these settings.
The patients then received a RII in a random double blind 
fashion, in the manner described below (see Methods 3.5).
3.4 MATERIALS
Gas supplied from the anaesthetic machine was delivered to the 
patients via a modified Mapleson A breathing system. The 
modification consisted of the addition of a two litre (2 1) 
black rubber anaesthetic reservoir bag in series with the usual 
reservoir bag. The reason for the inclusion of this bag is to 
allow the breathing system to be able to meet the demand of a 
rapid vital capacity breath (VCB) by the patient. The modified 
breathing system is shown in Figure 2.
The anaesthetic machine was adjusted by an assistant to deliver 
one of the following gas mixtures (as indicated by the slip of 
paper in a sealed envelope - see Section 3.3 above) -
- 2% isoflurane in 67% ^ 0  and 0^,
- 5% isoflurane in 0  ^ or
- 3,5% halothane in oxygen.
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Figure 21 Modified Mapleson A breathing system
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Total gas flow was set at 6 litres per minute (1/min). Once the 
settings had been made, the backbar (including the vaporiser) 
and the rotameters were covered with a green theatre towel. This 
made it impossible for the candidate to see which settings had 
been selected. In addition, all waste gas was actively scavenged 
to preclude the possibility of the candidate determining the 
anaesthetic mixture by smell.
Gas leaving the common gas outlet of the anaesthetic machine, 
and before entering the breathing system was humidified. 
Humidification was achieved by passing the gas through a hot 
water bath humidifier (Bennett Cascade 1 Humidifier, Puritan 
Bennett Corporation, USA) heated to approximately 60 degrees 
Celsius (’C). Dry gas at the common gas outlet had a temperature 
and relative humidity of 20°C and 15% respectively. These were 
increased to 27°C and 98% respectively by passage through the 
humidifier. Temperature and relative humidity were measured in a 
"bench-test trial" using a wet and dry bulb hygrometer placed in 
the stream of gas. After passage through the humidifier, the gas 
then entered the modified Mapleson A breathing system.
Each patient received a RII on the operating table in the manner 
described in Section 3.5 below. During the induction sequence 
the following were monitored -
38
- electrocardiogram (ECG) (Siemens Sirecust Monitor, 
Sweden)
- blood pressure (BP), recorded by means of continuous 
non-invasive finger probe (Finapress blood pressure 
monitor, BOC Health Care, USA)
- heart rate (HR)
- arterial oxygen saturation (Spf^)
- time from the onset of the induction to loss of
consciousness
- complications during the induction sequence.
Time was recorded to the nearest second (sec.) by means of a 
stopwatch. All the above observations were made by an assistant 
and recorded manually. The candidate carried out all the
inductions.
3.5 METHODS
The patient was placed on the operating table, an intravenous
(IV) cannula placed in a forearm vein and the monitoring
equipment described above attached. All IV drugs required for 
intravenous induction of anaesthesia were immediately available.
The gas flows and the vaporiser were set by the assistant and 
baseline recordings of HR, BP and SpO£ were made. The patient 
was then coached in the technique required for the RII as 
follows. Each patient was instructed to take as deep a breath as
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possible. This was carried out with only the black rubber 
facemask and angle-piece applied to the patient's face. Once 
this had been carried out, the patient was then instructed to 
exhale as far as possible before taking another deep breath (the 
vital capacity breath = VCB) and holding this breath for as long 
as possible. Both the above manoeuvres were carried out with the 
patient breathing room air. Once the patient understood the 
above sequence, the same procedure was repeated with the patient 
breathing the selected anaesthetic mixture.
The breathing system was primed by allowing the 61/min flow of 
carrier gas to flow through the system and then partially 
occluding the outlet of the system, until both reservoir bags 
were full, but not under tension. The outlet of the breathing 
system was connected to the angle piece already attached to the 
mask after the patient had exhaled to residual volume and before 
the patient took the VCB. The VCB that the patient then took 
contained the selected anaesthetic mixture. This breath was then 
held for as long as comfortable, before the patient resumed 
spontaneous respiration.
The time from the patient taking the VCB containing the 
anaesthetic mixture until the onset of loss of consciousness 
(defined below) was recorded by an assistant using a stopwatch.
Physiological parameters (HR, BP and SpOg) were recorded 
manually during the induction sequence. Specific note was made 
of the baseline levels (taken once the patient was settled on
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the operating table) and those at the time of loss of 
consciousness.
Loss of consciousness (LOC) was defined as lack of response to 
verbal commands, regular respiration and central pupils. This 
definition corresponds to the onset of surgical anaesthesia 
(stage 3) (as shown in Table 1, page 5). During the induction 
sequence the patient was asked by the candidate every ten 
seconds to open his/her eyes. When the patient no longer 
responded to these commands, the patient was observed for the 
onset or regular respiration. Once regular respiration had 
become established, the pupils were examined continuously. As 
soon as the pupils became central in position, the stopwatch was 
stopped. Time was recorded, representing the time to LOC.
In addition to the physiological parameters recorded any 
complications during the induction were also recorded. These 
complications included:
- coughing; this was deemed to have occurred if the 
patient made even a single cough. No differentiation 
was made between single or multiple coughs, unless the 
coughing was of such severity as to cause the induction 
to be abandoned - this was then recorded as an 
abandoned induction, with the reason stated as severe 
coughing;
- laryngospasm; being defined as any inspiratory
stridor not due to airway obstruction by the tongue;
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- restlessness/patient movement; being defined as 
patient movement requiring the patient to be physically 
restrained on the operating table;
- desaturation; being defined as a decrease in SpC^ 
to below 90%;
- secretions; being defined as when these were audible 
in the airway.
If the procedure was abandoned the reason for this was noted.
Following the onset of LOC, suxamethonium was administered and 
the patient intubated. Anaesthesia was then maintained in all 
cases with 2% halothane in 66% ^ 0  and 33% C^, with the 
patient breathing spontaneously.
All the patients were visited by the candidate approximately two 
hours post-operatively. The candidate was unaware of which agent 
the patient had received. At this time they were asked -
- what their last recall in the induction sequence was;
- if they had experienced any nausea or vomiting post 
operatively, and
- whether they would choose a RII again for a future 
anaesthetic (as an estimate of the acceptability of the 
technique by the patient). All the study participants 
were interviewed post-operatively, including those in 
whom the induction sequence had to be abandoned due to 
the severity of complications.
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The details described above during the induction sequence and 
for the post-operative interview were recorded manually on data 
sheets, an example of which is shown on the following page.
The data was then transferred to database files on the "Epistat" 
program on a Triton personal computer. These files were then 
used for the relevant statistical analyses.
3.6 STATISTICAL ANALYSIS
The following statistical tests were performed as appropriate, 
using the "Epistat" program on a Triton personal computer -
1. Analysis of variance (ANOVA). ANOVA was used to detect 
type 2 error when necessary (ie. to determine whether 
differences between groups were more significant than 
differences within groups). When ANOVA is used this is 
indicated in the relevant tables.
2. Paired and unpaired T-tests
3. Chi-squared tests (with Yates' correction when 
appropriate), and
4. Fischer's Exact test.
A p value of less than 0,05 was considered statistically 
significant. The results and the statistical tests performed to 
analyse the results are discussed in Chapter 4.
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RAPID INHALATIONAL INDUCTION STUDY Sample
DATA SHEET
Patient No ...............  PMH - Smoker Y N
Recent URTI Y N 
Age .......................  Chest disease Y N
Sex M F
Mass (kg) .......
ASA - 1 2 3
Procedure .......
Current medication
INDUCTION DETAILS
Agent - Hal 2% Iso in N2 O/O2
Complicated Y N
Complication -
- Coughing Y N
- Laryngospasm Y N
- Secretions Y N
- Excessive movement Y N
Abandoned Y N
5% Iso
Saturation (SPO2 ) Baseline/LOC 
Induction time (sec)
Number of breaths to LOC 
Mean arterial pressure (MAP) 
Heart rate
(onset of VCB - LOC)
Baseline/LOC 
Baseline/LOC
POST-OP INTERVIEW
- Would repeat experience Y N
- Amnesia after 1st VCB Y N
- Nausea and vomiting Y N
- Headache Y N
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CHAPTER 4 
RESULTS
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In the discussion of results obtained from this study, the study 
groups will be known as groups A, B and C. Group A received 3,5% 
halothane in oxygen, group B received 5% isoflurane in oxygen 
and group C received 2% isoflurane in ^ 0  and 0^.
4.1 DEMOGRAPHIC DATA
The mean ages and standard deviations (SD) for the three 
groups, in years, are as follows - group A 25,40 (12); group B 
25,15 (8,9) and group C 23,45 (6,4). These values are obtained 
from the raw data presented in Table 3. Unpaired t-tests and 
ANOVA did not reveal any significant differences between the 
means of these groups.
The male to female ratios in the three groups are as follows - 
group A, 12 males and 8 females; group B, 12 males and 8 females 
and group C, 14 males and 6 females. Chi-squared testing 
showed the groups to be comparable with regard to gender ratios 
(see Table 4).
The mass, mean (SD), of the three groups is shown in 
kilograms (kg) in Table 5. The values are as follows - group A, 
64,35 (12); group B 62,65 (9) and group C 61,95 (9). Unpaired 
t-testing and ANOVA showed there to be no significant 
differences between the three groups with regard to the 
subjects' masses.
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Table 3.
Subject ages in years
Mean 
+ /-SD
A. B. C.
Halothane 3,5% Isoflurane 5% Isoflurane 2% N2O/O2n = 20 n = 20 n = 20
14 17 14
16 18 16
16 18 17
18 19 18
19 19 19
21 21 20
21 21 21
21 21 21
22 24 23
22 24 24
22 25 24
22 25 24
23 27 24
23 27 25
26 27 26
28 29 27
34 33 33
34 34 34
38 38 36
69 55 38
25,40 25,15 23,45
12 8,9 6,4
Unpaired t tests. ANOVA
A vs B P = 0,940 0,917
B vs C P = 0,492 0,444
A vs C P = 0,526 0,609
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Table 4.
Male/Female ratios.
A. B.
Halothane 3,5% Isoflurane 5% 
n = 20 n = 20
Male/Female
12/8 12/8
Chi-squared test.
A vs B P = 0,747 
B vs C P = 0,740 
A vs C p = 0,740
c.
Isoflurane 2% N2O/O2 
n = 20
14/6
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Table 5.
Subject Mass in Kilograms
A B c
Halothane 3,5% Isoflurane 5% Isoflurane 2% N2O/O2
n = 20 n = 20 n = 20
45 45 50
47 52 51
49 53 52
50 55 53
51 55 53
54 56 54
57 57 55
64 58 55
65 59 58
65 60 60
66 64 60
67 65 65
70 65 65
72 68 70
74 69 70
75 71 70
75 74 72
76 75 74
76 76 76
89 76 76
Mean 64,35 62,65 61,95
+ \-  SD 12 9 9
Unpaired t tests ANOVA
A vs B P = 0,671 0,671
B vs C P = 0,857 0,857
A vs C P = 0,575 0,575
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The number of smokers in each group was as follows - group A, 
7 out of 20; group B, 7 out of 20 and group C, 8 out of 20. 
Chi-squared testing did not reveal any significant differences 
between the groups with regard to the number of smokers in each 
group. The p values obtained are shown in Table 6.
American Society of Anesthesiologists (ASA) physical status of
the three groups is as follows - group A, 18 subjects ASA 1, and 
2 subjects ASA 2; group B, 20 subjects ASA 1 and group C, 18 
subjects ASA 1 and 2 subjects ASA 2. Fischer's Exact Tests 
showed there to be no significant differences between the groups 
with regard to physical status (see Table 7).
From the above, it is evident that the three groups are 
demographically comparable with regard to age, mass, gender 
ratio, ASA status and the number of smokers. This is due to the 
homogeneous, well-defined group of subjects (young patients 
presenting for day-case dental surgery) entered into the study. 
None of the subjects had any pre-existing respiratory pathology 
of note and none were receiving any medication pre-operatively.
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Table 6.
Number of Smokers
A B C
Halothane 3,5% Isoflurane 5% Isoflurane 2% N2 O/O2
n = 20 n = 20 n = 20
7 7 8
Chi squared tests 
A vs B p = 0,740
B vs C p = 1
A vs C p = 1
Table 7.
American Society of Anesthesiologists (ASA) Physical 
Status Classification_____________________________
A B C
Halothane 3,5% Isoflurane 5% Isoflurane 2% N2 O/O2
n = 20 n = 20 n
ASA 1 18 20 18
ASA 2 2 0 2
Fisher’s Exact Test
A vs B P = 0,243
B vs C P = 0,243
A vs C P = 0,697
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4.2 THE INDUCTION PERIOD
Table 8 and Figure 3 depicts the raw data regarding the speed 
of induction in the three groups. The mean (SD) induction times 
in seconds are as follows - group A, 176 (36); group B 121 (50) 
and group C, 134 (41). Analysis of variance (ANOVA) and 
unpaired t-tests showed there to be a significant difference in 
induction times between group A and both groups B (p = 0,0007) 
and group C (p= 0,003). However, there is no significant 
difference in induction time between groups B and C (p = 0,443).
The number of breaths to loss of consciousness (L0C), mean 
(SD), in each group are as follows - group A, 30 (12); group B, 
18 (12) and group C, 23 (8). The raw data from which these 
figures are derived are listed in Table 9 and Figure 4. As is 
the case with the speed of induction, there is a significant 
difference between the number of breaths to L0C between group A 
and group B (p = 0,005). There is no significant difference 
between groups A and C (p = 0,06) or B and C (p = 0,139). The p 
values were determined using unpaired t-tests and ANOVA.
The data for both the speed of induction and the number of 
breaths to L0C include only those data obtained from subjects 
completing the induction sequence.
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Table
Speed
(Time
Mean
+ \-  SD
8.
of Induction
in seconds to loss of consciousness)______
A B C
Halothane 3,5% Isoflurane 5% Isoflurane 2% N2O/O2
n = 17 n = 18 n = 16
90 45 45
120 60 90
140 75 90
158 76 120
175 80 120
176 83 122
177 86 132
180 89 132
180 114 135
180 120 135
182 125 136
183 135 142
190 165 147
191 172 180
218 180 205
221 182 210
240 197
202
176 121 134
36 50 41
A vs B
Unpaired t tests 
p = 0,0007
ANOVA
0,0007
B vs C p = 0,443 0,443
A vs C p = 0,003 0,003
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Speed of Induction
Figure 3
Time to Loss of Conaciouanaaa in Saconda
p < 0,05
A VS B 176 121 134
A VS C (♦/- 36) (♦/- 50) (♦/- 41)
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Table 9.
Number of breaths to loss of consciousness
A. B. c.
Halothane 3,5% Isoflurane 5% Isoflurane 2% N2O/O2
n = 17 n = 18 n = 16
7 3 15
20 5 15
20 0 15
20 10 15
24 10 17
25 12 20
25 13 20
25 15 20
28 15 24
29 15 26
30 15 26
34 15 30
40 20 31
44 20 31
45 28 35
50 30 40
50 35
50
Mean 30 18 23
+  / -S D 12 12 8
Unpaired t tests ANOVA
A vs B P = 0,005 0,005
B vs C P = 0,139 0,139
A vs C P = 0,06 0,06
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Loss of Consciousness
Figure 4
Number of Breaths
p  < 0 ,0 5
A vs B 30 10 23
( ♦ / -  12) ( ♦ / -  12) ( ♦ / -  8 )
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4.3 COMPLICATIONS DURING INDUCTION
Table 10(a) shows the number of complicated inductions in each 
group. There were 9 out of 20 complicated inductions in both 
groups A and B, and only 4 out of 20 complicated inductions in 
group C. Chi-squared tests (with Yates' correction) did not 
reveal any significant differences between the three groups 
with regard to total number of complicated inductions. There 
were also no significant differences between the types of 
complications during the induction sequence, between the 
groups. These are listed in Table 10(b). The p values obtained 
comparing the types of complications were determined by the 
Fischer's Exact Test.
There were no significant differences between the groups with 
regard to the number of inductions which had to be abandoned, 
as determined by Fischer's Exact Test The relevant p values 
are shown in Table 11. Of the 3 inductions which had to be 
abandoned in group A, 1 had to be abandoned due to uncontrolled 
coughing and 2 because of excessive movement, requiring 
restraint of the patient. In group B, both the abandoned 
inductions were due to uncontrolled coughing. In group C, 4 
inductions were abandoned, all due to excessive patient movement 
and restlessness.
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Table 10.
a). Complicated Inductions
A. B.
Halothane 3,5% Isoflurane 5% 
n = 20 n = 20
9 9
Chi - squared tests.
A vs B p = 0,750
B vs C p = 0,177
A vs C p = 0,177
Table 10.
b). Types of Complications
A. B.
Halothane 3,5% Isoflurane 5%
n = 9 n = 9
Coughing 5 3
Secretions 0 1
Excessive
movement
5 6
Fisher’s Exact Tests:
1. Coughing 2. Secretions
A vs B p = 0,318 A vs B p = 0,526
B vs C p = 0,294 
A vs C p = 0,09
B vs C p = 0,714
c.
Isoflurane 2% N2O/O2 
n = 20
4
C.
Isoflurane 2% N2O/O2 
n = 4
0
0
4
3. Excessive 
movement
A vs B p = 0,5 
B vs C p = 0,294 
A vs C p = 0,176
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A. B.
Halothane 3,5% Isoflurane 5% 
n = 20 n = 20
3 2
Table 11.
Abandoned Inductions______
Fisher’s Exact Test
A vs B p = 0,499
B vs C p = 0,331
A vs C p = 0,499
C.
Isoflurane 2% N2O/O2 
n = 20
4
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Smokers were well represented within the subjects in whom 
inductions had to be abandoned due to the severity of 
complications. In group A, out of the three inductions 
abandoned, one of the subjects was a smoker. This was also true 
for both the inductions abandoned in group B and all the 
inductions abandoned in group C. If all the smokers from groups 
A, B and C are compared to the non-smokers from the same groups 
with regard to number of inductions abandoned, there is no 
significant difference (p=0.09 by Fisher's exact test - Table 
12).
There were no episodes of desaturation (Spl^ <90%) or 
laryngospasm in any of the groups. Excessive secretions 
complicated only one of the inductions - in group B.
4.4 CARDIOVASCULAR PARAMETERS DURING THE INDUCTION
SEQUENCE
Table 13 and Figure 5 (mean arterial pressure), and Table 14 
and Figure 6 (heart rate), show the raw data regarding the 
baseline and post-induction (at LOC) values for MAP and HR for 
the three groups. Paired t-tests and ANOVA, within groups, 
and unpaired t-tests and ANOVA, between groups, showed there 
to be no significant differences in the mean values for MAP, 
either between groups A, B and C or within groups A and B 
(baseline vs. post-induction). However, there was a significant 
decrease from baseline to post-induction MAP in group C (p =
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Table 12.
Abandoned Inductions.
Smokers vs Non-smokers._____
Not Abandoned
Smoker 15
n = 22
Non-smoker 36
n = 38
Fisher’s Exact test 
Smokers vs Non-smokers
p = 0,09
Abandoned
7
2
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Table 13.
Mean Arterial Pressure (MAP)
(1) Pre Induction
(2) At loss of consciousness (LOC)
A B c
Halothane 3,5% Isoflurane 5% Isoflurane 2% N2O/O2
n = 17 n = 18 n == 16
1 2 1 2 1 2
69 104 73 92 82 88
72 78 81 92 83 67
73 64 82 86 83 79
76 85 83 68 86 76
76 93 85 59 86 80
81 72 86 82 90 88
85 73 87 76 91 86
86 78 88 84 92 83
86 86 92 102 95 77
88 77 94 80 97 97
94 95 99 87 100 72
95 84 100 103 106 93
98 96 102 92 109 75
100 90 102 110 111 100
100 105 104 94 120 97
107 115 107 92 121 97
113 81 108 109
123 102
Mean 88 86,8 94,2 89,4 97 84,7
+ \-SD 13 13,3 12,4 13,5 13 10
Paired t tests. ANOVA Unpaired t tests. ANOVA
A1vsA2 p = 0,708 0,765 A1vsB1 P = 0,166 0,166
B1vsB2 p = 0,114 0,277 B1vsC1 P = 0,527 0,527
C1vsC2 p = 0,0004 0,005 A1vsC1 P = 0,058 0,058
A2vsB2 P = 0,568 0,568
B2vsC2 P = 0,259 0,259
A2vsC2 P = 0,609 0,609
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Mean Arterial Pressure (MAP).
Figure 5
MAP (mmHg)
126 i------------------
HALOTHANE 3.5% ISOFLURANE 5% ISOFLURANE 2%
Pre-induction {M l Loss of Consc.
63
Table 14.
Heart Rate (HR)
(1) Pre Induction
(2) At loss of consciousness (LOC)
A B C
Halothane 3,5% Isoflurane 5% Isoflurane 2% N2O/O2
n = 17 n = 18 n = 16
1 2 1 2 1 2
59 66 52 53 61 61
61 60 54 70 62 62
61 74 58 67 63 75
63 72 58 80 68 73
63 81 60 49 69 60
66 80 60 74 74 86
69 95 67 78 75 61
72 89 68 74 75 65
74 81 70 80 75 68
75 74 72 104 77 117
78 76 82 85 84 76
79 76 85 99 87 53
81 72 86 91 88 75
86 95 88 108 88 85
88 100 91 90 96 53
100 84 93 80 153 108
104 92 113 117
114 106
Mean 75 80 76 83 80 74
+ \-SD 13 11 19 18 22 18
Paired t tests. ANOVA Unpaired t tests. ANOVA
A1vsA2 p = 0,080 0,226 A1vsB1 p = 0,868 0,868
B1vsB2 p = 0,024 0,257 B1vsC1 p = 0,499 0,499
C1vsC2 p = 0,224 0,342 A1vsC1 p = 0,369 0,369
A2vsB2 p = 0,577 0,577
B2vsC2 p = 0,149 0,149
A2vsC2 p = 0,230 0,230
64
Heart Rate (HR).
Figure 6
80
60
40
20
0
100
HR (baata par Min.)
HALOTHANE 3,5% ISOFLURANE 5% ISOFLURANE 2% 
■ i  PRE INDUCTION LOSS CONSCIOUSNESS
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0,0004). Group B showed the only significant difference in HR (p 
= 0,024) with an increase from baseline to post-induction levels 
of HR. The data pertaining to the cardiovascular parameters 
includes only those data obtained from subjects who completed 
the induction sequence.
4.5 POST-OPERATIVE INTERVIEW
Table 15 lists the results of the post-operative interview. 
These results contain the responses of all the subjects included 
in the study, regardless of whether the induction had to be 
abandoned or not.
Most of the subjects had amnesia for events following the 
vital capacity breath (VCB) containing the anaesthetic mixture - 
15 out of 20 in group A, 16 out of 20 in group B and 14 out of 
20 in group C. There were no significant differences between the 
groups with regard to the incidence of amnesia as determined by 
Fischer's Exact Test.
Most of the subjects, 14 out of 20 in group A and 17 out of 20 
in groups B and C, found the experience of RII not unpleasant 
and were prepared to repeat the experience for a subsequent 
anaesthetic.
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Table 15.
Post operative interview
A B
Halothane 3,5% Isoflurane 5% 
n = 20 n = 20
Amnesia after 
1st Vital Capacity 
Breath 15
(Number)
Would repeat 
experience 14
(Number)
Headache
(Number)
3
Nausea &
Vomiting
(Number)
1
Fisher’s Exact Test
Amnesia A
B
A
Would 
repeat the 
Experience A
B
A
Headache A
B
A
Nausea and 
Vomiting A
B
A
16
17
1
0
vs B P = 0,5
vs C P = 0,338
vs C P = 0,499
vs B P = 0,225
vs c P = 0,669
vs c P = 0,225
vs B P = 0.302
vs C P = 0,756
vs C P 0,302
vs B P = 0,499
vs C P = 0,999
vs C P = 0,499
C
Isoflurane 2% N2O/O2 
n = 20
14
17
1
0
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The incidence of post-operative complications was low - 
headache occurred in 1 subject in both groups B and C, and in 3 
subjects in group C. Nausea and vomiting occurred in only 1 
subject from group A. There were no significant differences 
between groups with regard to types of post-operative 
complications (headache or nausea and vomiting) (Table 15).
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CHAPTER 5
DISCUSSION
AND CONCLUSIONS
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In essence, this study was undertaken to address one of the
problems presented by the considerable prejudice developing 
against the use of halothane in Europe and North America v '.
The safety and efficacy of halothane as an agent for both
conventional (CII) and rapid inhalational induction (R11) has
been well proven (16,17,24)^ However isoflurane is replacing 
halothane as the volatile agent of choice and has the reputation 
of being a difficult agent to use for CII (12,27) isofiurane 
has also been used for RII, but only when administered to 
heavily premedicated patients or when the inspired
concentration of the agent was limited by the addition of 
nitrous oxide ^ 0 )  in the inspired mixture Avoiding
the emotive aspects of the decline of halothane as the volatile 
agent of choice for inhalational induction, the candidate wished 
to investigate the possibility of using isoflurane for RII.
RII as a technique is not new. It was introduced into clinical 
practice for use with cyclopropane in 1954 Although
cyclopropane is still available in some countries, it is rarely 
used in clinical practice today because it is highly flammable. 
RII has therefore had to wait for the development of the 
fluorinated volatile agents with low B/G solubility to be 
revived. This revival occurred in 1982, when RII was described 
by Ruffle and co-workers with halothane. As discussed in
Chapter 2, the application of the technique of RII is limited, 
as is the literature regarding this technique. However, RII has
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a definite place as an alternative to intravenous induction, as 
well as in the day-case setting.
A previous study by the candidate and others showed that 
humidification of the carrier gas during inhalational induction 
with isoflurane decreased the respiratory tract side effects 
produced by the pungency of the agent. The question then arose 
whether it would be possible to administer a high concentration 
of isoflurane, as would be required for RII, if the carrier gas 
were humidified.
The three study groups in the present study were well matched as 
to demographic criteria as seen in Tables 3 to 7. Also, all the 
subjects were unpremedicated and presenting for very similar 
surgery by the same surgeon at the same hospital. All the 
anaesthetic inductions were carried out by the candidate. 
Interfering variables were reduced to a minimum and it can be 
assumed that any differences between the study groups are due to 
the different agents used. It should be noted that with regard 
to the demographic data none of the groups included patients who 
smoked more than twenty cigarettes per day. Although there is no 
supporting evidence, it may be argued that a smoker of up to 20 
cigarettes per day should be classified as ASA physical status 
2. The candidate chose to ignore this and only classify the 
subjects as physical status ASA 2 if systemic disease was 
present, whether this was due to cigarette smoking or not.
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The results of the post-operative interview (Table 15) show that 
patient acceptance is high and that most patients would repeat 
the experience of RII in the future if the occasion arose. A 
very low incidence of post-operative complications occurs in 
these patients. These results may be criticised on the basis 
that they were obtained by interview and not by anonymous 
questionnaire. However, the answers were obtained by the 
candidate asking the subjects open-ended questions wherever 
possible eg."Are you experiencing any discomfort or any other 
problems now that the operation is over?". There were no 
significant differences between the three study groups with 
regard to post-operative complications, but the numbers involved 
are very small and a larger study would be necessary to obtain 
more meaningful results in this regard. It is impressive that 
80% of all the subjects studied found the experience of RII not 
unpleasant, despite the fact that post-operative pain may have 
caused this response to be biased against a favourable answer. 
Before further discussion then, it would appear that the 
patients included in the study did not find the experience 
unpleasant. This is in keeping with the study by Lamberty and 
Wilson using isoflurane in ^ 0  and oxygen (0^)
As anticipated from the physical properties (Table 2) of 
halothane and isoflurane, this study showed that halothane 
produces a significantly slower RII than isoflurane. This 
difference is significant whether isoflurane is administered in 
high concentration in oxygen (4,5, MAC) or as a lower
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concentration in ^ 0  and Og. There is no significant 
difference in speed of induction between RII with 5% isoflurane 
in oxygen or 2% isoflurane in N^O and 0^ (Table 8, Figure 
3). Presumably this is because the second gas effect 
provided by ^ 0  is sufficient to compensate for the more rapid 
rise in alveolar concentration produced by inhaling a higher 
concentration of isoflurane. Although isoflurane produces a 
faster onset of surgical anaesthesia than halothane when used 
for RII the following questions now arise -
- what, if any, is the clinical advantage of the 
increased speed of induction with isoflurane?, and
- would a larger study population show the same 
differences without the large standard deviations 
observed in this study? (Table 8)
It is the clinical impression of the candidate that patients who 
are not anxious and who are not smokers are better able to 
comply with the technique of RII, and in particular with holding 
the VCB containing the volatile agent. If the study had been 
designed to exclude all smokers and anxious patients it is 
possible that the wide standard deviations observed in induction 
time may well have not occurred. As no objective measure of 
anxiety was included in the study design, it is not possible, in 
retrospect, to exclude anxious subjects from the statistical
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analyses. The findings of the study (Table 12) do not support 
the candidate's clinical impression that more inductions had to 
be abandoned in patients who smoke cigarettes.
The number of breaths that the subjects required to take before 
the onset of LOC (Table 9, Figure 4) support the findings 
described above regarding induction time (defined in chapter 3, 
page 40). This is not surprising, as the longer the induction 
time involved, the longer the subject would have to take 
additional breaths before LOC ensued. It is interesting though 
that there is no significant difference between the halothane 
group and the 2% isoflurane group with regard to the number of 
breaths before loss of consciousness - despite there being a 
small, but significant difference in induction times.
The definition of LOC chosen by the candidate for this study, 
namely no response to verbal command, regular respiration and 
central pupils coincides as far as possible with the 
definition of stage 3 of anaesthesia (Table 1), or surgical 
anaesthesia. This is not in keeping with any of the previous 
studies of RII (16-18,20,22,25)^ t^at is a relatively
"soft" end point, rather than an end-point such as the loss of 
the eyelid reflex etc. previously used. The candidate preferred 
the use of stage 3 of anaesthesia as the definition of LOC, as 
this is a more clinically relevant definition. This is the point 
at which body surface surgery may commence as occurs in the 
day-case setting. More time is required to reach stage 3 of
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anaesthesia than to reach the end-points as defined in the 
previous studies of RII. Therefore, the induction times and 
related measurements (number of breaths to LOC) obtained in this 
study are longer than those described in the studies by Ruffle 
and associates Lamberty and Wilson and
Rowbottom and colleagues It should be noted though that
a large proportion of patients have amnesia for events after 
the first vital capacity breath containing volatile agent 
(Table 15), and therefore, as far as the subject is concerned, 
he is no longer conscious after the first breath. This is in 
keeping with previous descriptions of this technique as the 
"single breath technique" jf ^ g  candidate had access
to a volatile agent analyser and automatic breath-by-breath data 
collection system it would have been possible to plot the rate 
of rise of volatile agent concentration in inhaled and exhaled 
gases and to correlate these levels with the onset of LOC as has 
previously been documented with halothane
The cardiovascular stability of subjects who undergo RII is 
remarkable and well demonstrated by this study (Tables 13 and 
14, Figures 5 and 6). The only significant decrease in mean 
arterial pressure (13%) occurred in subjects receiving 2% 
isoflurane in ^ 0  and O 2 . This degree of hypotension is 
similar to that seen when intravenous agents are used for 
induction of anaesthesia and it is unlikely that it represents a 
threat to the well-being of the patient. It may be prudent, 
however, to avoid this combination for RII in patients who have
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ischaemic or valvular heart disease. It should also be noted 
that there is no tachycardia associated with this mild decrease 
in blood pressure. This also suggests that the decrease in blood 
pressure should not detract from the advantages of the technique 
of RII with 2% isoflurane in ^ 0  and 02. 5% isoflurane in 
02, when used for RII, produces a small (± 9%) but significant 
increase in heart rate, in keeping with the pharmacological 
action of this drug Again, this does not represent a
threat to the cardiovascular safety of most patients.
Complications related to the airway appear to be common with RII 
in this study ie 45% in groups A and B and 20% in group C 
(Tables 10a and 10b). The candidate believes this is 
attributable not only to the technique of RII, but also to the 
rigid criteria by which the complications were defined. It will 
be noted that there were no significant differences between the 
study groups with regard to complication rate - this despite the 
poor reputation isoflurane has for producing respiratory tract 
irritation. The findings of this study suggest that 
humidification of the carrier gas does decrease the pungency of 
isoflurane to such a degree that the associated complication 
rate is similar to that seen when halothane is used. However, a 
further study would be required, comparing RII with isoflurane 
in humidified and non-humidified carrier gas, to clarify the 
effect of humidification on complication rate when isoflurane is 
used for RII. A similar study has shown the beneficial effect of 
humidification of the carrier gas for conventional inhalational
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. That the complicationsinduction with isoflurane 
associated with RII were not severe is supported by the high 
acceptance rate of subjects for this technique regardless of the 
agent used (Table 15) and the small number of inductions which 
had to be abandoned due to the complications (Table 11).
The nature of the complications (Table 10b) encountered during
RII is interesting in that the subjects in Group C (2%
isoflurane in N 20 and 0 2) experienced only excessive
movement/restlessness and not the expected complications of
coughing and excessive secretions , as seen in the other two
groups. This may be due to the presence of nitrous oxide in
the inhaled mixture - N20 has a very low B/G solubility
coefficient (Figure 1), but is not very potent (MAC=105%) 
(311 (231v '. As explained by Drummond ' ', N20 may rapidly 
induce stage 2 (phase of excitement) of anaesthesia, before the 
concentration of isoflurane in the brain is sufficient to 
produce surgical anaesthesia. During this transient phase, while 
the N20 is exerting its effect and before the isoflurane has 
anaesthetised the patient sufficiently, the patient may exhibit 
all the features of stage 2 anaesthesia (shown in Table 1), 
including restlessness. The restlessness observed in the 
subjects receiving N20 in this study was of such severity as 
to result in the abandonment of all the inductions in which 
restlessness occurred. The inductions which had to be abandoned 
due to complications in the 5% isoflurane group were due to 
respiratory complications (coughing and excess secretions), and
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those in the halothane group due to both excessive movement and 
respiratory complications. This may indicate that as 5% 
isoflurane results in a faster RII than halothane, the subject 
spends less time in stage 2 of anaesthesia and therefore 
exhibits less of the complications associated with that stage ie 
restlessness/excessive movement. It is important to note that 
not one episode of desaturation or laryngospasm occurred during 
this study. This, together with the already noted cardiovascular 
stability, attests to the safety of RII.
In conclusion then, it can be stated that RII is a safe 
technique, which is well accepted by patients regardless of
whether halothane or isoflurane is used. 5% isoflurane in oxygen 
produces the fastest RII, with a low rate of complications and 
abandoned inductions. The speed of induction approaches that 
associated with intravenous induction. This makes RII a viable 
alternative to intravenous induction as well as to Cl I. The 
study also shows that isoflurane is a useful alternative to 
halothane for RII. 2% isoflurane in ^ 0  and 0^ offers no
advantage over 5% isoflurane in oxygen in terms of speed of 
induction, and it is associated with marked restlessness during 
induction of anaesthesia. This is probably due to the presence 
of ^ 0  in the inhaled gas mixture. A cooperative subject is
required to carry out RII successfully and therefore, the 
technique is not useful in children and unwilling subjects. 
Until proven otherwise, it would be better to avoid RII also in 
subjects who are anxious or who smoke cigarettes. This study
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proves that it is not necessary to heavily premedicate subjects 
in order to tolerate RII with isoflurane. This, together with 
the speed of induction obtained when 5% isoflurane is used, 
makes RII a potentially useful technique for day-case 
anaesthesia. It may be argued whether the improved speed of 
induction with isoflurane compared to halothane is clinically 
significant and whether halothane would therefore be as useful 
as isoflurane in this role. As intravenous agents would not be 
required if RII were used, it is possible that the slightly 
longer induction provided for by RII compared to the intravenous 
agents would be offset by a shorter recovery period in the 
subject receiving only volatile agent and no IV agents. This 
provides the basis for further study (ie. RII vs IV induction).
79
APPENDIX
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SOME DEFINITIONS
MINIMUM ALVEOLAR CONCENTRATION (MAC)
The alveolar concentration of agent at one atmosphere needed to 
abolish movement in 50% of subjects in response to a noxious 
stimulus (32).
SECOND GAS EFFECT - (related to nitrous oxide)
During induction of anaesthesia with anaesthetic gases and 
volatile agents, uptake of nitrous oxide exceeds the elimination 
of nitrogen. This increases the alveolar concentrations of other 
gases, including oxygen and volatile anaesthetic agents. The 
uptake of the other gases is then enhanced due to the increased
( 3 0  3 3 )
alveolarrblood concentration gradient v ’ '.
ASA CLASSIFICATION OF PHYSICAL STATUS (34)
Class Physical status
I A healthy patient with no systemic disease process
II A patient with a mild to moderate systemic disease
process caused either by the condition to be treated 
surgically or other pathological process and which does 
not limit the patient's activities in any way eg. mild 
diabetic, treated hypertensive, or heavy smoker
III A patient with a severe systemic disturbance from any 
cause, and which imposes a definite functional 
limitation on him or her eg. ischaemic heart disease 
with a limited exercise tolerance, severe chronic 
obstructive airways disease with dyspnoea on exertion
IV A patient with a severe systemic disease which is a
constant threat to life eg. the chronic bronchitic who 
is dyspnoeic at rest, advanced chronic liver failure
V A moribund patient who is unlikely to survive 24 hr
with or without surgery
E Emergency operation. Any patient in any of the above
classes who is operated on as an emergency is regarded 
as being in poorer physical condition, and the letter E 
is prefixed
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